Ask OpenScientist

Ask a research question about Conduct Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
7
Phenotypes
17
Pathograph
6
Treatments
3
Subtypes
4
Differentials
3
Datasets
3
Trials
1
Deep Research

Subtypes

3
DSM-5 age-of-onset specifier
Childhood-onset conduct disorder
Conduct-disorder subtype where at least one conduct-disorder symptom is present before age 10 years; this specifier is clinically important for prognosis and service planning.
Show evidence (1 reference)
clinicaltrials:NCT02828969 PARTIAL Human Clinical
"The Trajectories project is designed to describe children and adolescents with disruptive behaviors, their care management and to follow their life trajectory and psychiatric evolution after admission to emergency rooms."
The trajectory study supports child and adolescent CD-spectrum presentations; the age-of-onset threshold is a DSM clinical specifier.
Adolescent-onset conduct disorder
Conduct-disorder subtype where conduct-disorder symptoms emerge in adolescence without symptoms before age 10 years.
Show evidence (1 reference)
clinicaltrials:NCT02828969 PARTIAL Human Clinical
"The Trajectories project is designed to describe children and adolescents with disruptive behaviors, their care management and to follow their life trajectory and psychiatric evolution after admission to emergency rooms."
The trajectory study supports adolescent CD-spectrum presentations; the age-of-onset threshold is a DSM clinical specifier.
DSM-5 specifier
Conduct disorder with limited prosocial emotions
Conduct-disorder specifier marked by persistent callous-unemotional traits such as low remorse, low empathy, shallow affect, or limited concern about performance; this subgroup has greater antisocial risk and symptom severity.
Show evidence (1 reference)
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"Children with callous‐unemotional (CU) traits are at high lifetime risk of antisocial behavior."
Meta-analysis background supports CU traits as a clinically meaningful limited-prosocial-emotions specifier.

Pathophysiology

8
Intergenerational Polygenic Liability
Conduct problems show polygenic transmission from parental characteristics to child conduct problems, supporting a heritable liability component embedded in family development.
Show evidence (2 references)
DOI:10.1038/s41380-023-02383-7 SUPPORT Human Clinical
"The aetiology of conduct problems involves a combination of genetic and environmental factors, many of which are inherently linked to parental characteristics given parents’ central role in children’s lives across development."
Trio study frames conduct problems as genetically and environmentally influenced.
DOI:10.1038/s41380-023-02383-7 SUPPORT Human Clinical
"We found significant genetic transmission effects on conduct problems for 12 out of 13 PGS at age 8 years"
The MoBa trio analysis supports genetic transmission effects.
Childhood Aggression Genetic Architecture
Persistent aggression, a central conduct-disorder behavior domain, has substantial genetic contribution, but candidate-gene and GxE findings are heterogeneous and not ready for deterministic interpretation.
Show evidence (2 references)
DOI:10.1038/s41398-024-02870-7 SUPPORT Human Clinical
"While half of the variance in childhood aggression is attributed to genetic factors, the biological mechanism and the interplay between genes and environment that results in aggression remains elusive."
Systematic review supports genetic contribution but emphasizes unresolved mechanisms.
DOI:10.1038/s41398-024-02870-7 SUPPORT Human Clinical
"investigation of candidate genes, especially of MAOA (17 studies), DRD4 (13 studies), and COMT (12 studies) continue to dominate the field"
Review identifies commonly studied aggression candidate genes.
Amygdala-Mediated Empathy Deficit
In the conduct-disorder subgroup with callous-unemotional traits, deficient empathy is linked to reduced amygdala responses to fearful facial expressions and impaired recognition of distress in others.
neuron link
amygdala link
Show evidence (2 references)
PMID:25470696 SUPPORT Human Clinical
"Deficient empathy shows a particularly selective association with conduct disorder accompanied by callous–unemotional traits."
NEJM review identifies deficient empathy as selective for the callous-unemotional conduct-disorder subgroup.
PMID:25470696 SUPPORT Human Clinical
"Deficient empathy is related to amygdala dysfunction."
NEJM review links the deficient-empathy mechanism to amygdala dysfunction.
Threat-Circuit Hypersensitivity
Youth with conduct disorder who do not have callous-unemotional traits can show heightened threat-circuit responsiveness across the amygdala-hypothalamus-periaqueductal gray pathway, increasing risk of hostile attribution, frustration sensitivity, and reactive aggression.
neuron link
amygdala link hypothalamus link central gray substance of midbrain link
Show evidence (2 references)
PMID:25470696 SUPPORT Human Clinical
"The subgroup without callous–unemotional traits exhibits a different pattern, with atypically elevated threat-circuitry responsiveness"
NEJM review identifies heightened threat-circuit responsiveness in the conduct-disorder subgroup without callous-unemotional traits.
PMID:25470696 SUPPORT Human Clinical
"the amygdala is part of a circuit, encompassing the hypothalamus and periaqueductal gray matter, that mediates graded responses to threats"
NEJM review defines the threat-response circuit containing amygdala, hypothalamus, and periaqueductal gray matter.
Striato-vmPFC Decision-Making Deficit
Conduct problems are associated with impaired reinforcement-based decision-making, including deficient negative-prediction-error signaling and deficient recruitment of the striatum and ventromedial prefrontal cortex.
neuron link
striatum link prefrontal cortex link
Show evidence (2 references)
PMID:25470696 SUPPORT Human Clinical
"Persons who fail to learn how to make choices that lead to rewards rather than punishments are at high risk for impulsivity, frustration, and reactive aggression."
NEJM review links deficient reward-punishment learning to impulsivity, frustration, and reactive aggression.
PMID:25470696 SUPPORT Human Clinical
"youth with conduct problems show deficits in negative-prediction-error signaling, manifested by deficient recruitment of the striatum and ventromedial prefrontal cortex."
NEJM review identifies striatal and ventromedial prefrontal recruitment deficits during reinforcement learning.
Persistent Antisocial and Aggressive Behavior
The core behavioral mechanism is persistent violation of rules and rights, often expressed through aggressive, antisocial, or defiant behavior that requires social, clinical, and sometimes justice-system response.
neuron link
amygdala link prefrontal cortex link
Show evidence (4 references)
clinicaltrials:NCT02828969 SUPPORT Human Clinical
"Conduct disorders are defined as "repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate norms are violated"."
ClinicalTrials.gov trajectory study provides a concise conduct-disorder behavioral definition.
clinicaltrials:NCT00676429 SUPPORT Human Clinical
"The main characteristic of these disorders is a repetitive and persistent pattern of antisocial, aggressive or defiant behavior that involves major violations of age-appropriate expectations or norms."
Trial background supports the aggressive and antisocial behavior node.
PMID:25470696 SUPPORT Human Clinical
"Youth conduct problems are predictive of an increased risk of substance abuse, criminal behavior, and educational disruption"
NEJM review documents the long-term antisocial outcomes of conduct problems.
+ 1 more reference
Callous-Unemotional Trait Severity
Callous-unemotional traits identify a clinically important disruptive behavior subgroup with higher antisocial risk and greater symptom severity, while still showing improvement in disruptive behavior symptoms with treatment.
Show evidence (4 references)
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"Children with callous‐unemotional (CU) traits are at high lifetime risk of antisocial behavior."
Meta-analysis background supports CU traits as a risk/severity dimension.
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"DBD+CU children improve with treatment, but their greater DBD symptom severity requires specialized treatment modules that could be implemented alongside parenting programs."
Meta-analysis conclusion supports CU traits as a clinically relevant modifier of severity and treatment planning.
PMID:25470696 SUPPORT Human Clinical
"Callous–unemotional traits, which occur in fewer than half of young persons with conduct disorder, identify a subgroup with distinctive clinical features and neurocognitive perturbations."
NEJM review establishes CU traits as identifying a distinctive subgroup with unique neurocognitive features.
+ 1 more reference
Psychosocial Intervention Response
Evidence-based parent-management and parent-child interventions reduce disruptive behavior, indicating that family and social-learning mechanisms are modifiable downstream contributors.
Show evidence (1 reference)
DOI:10.1007/s10578-022-01367-y SUPPORT Human Clinical
"Results showed that PMT (g = 0.64 [95% CI 0.42, 0.86]) and PCIT (g = 1.22 [95% CI 0.75, 1.69]) were more effective than waiting-list (WL) in reducing parent-rated disruptive behavior"
Meta-analysis supports parent-focused intervention effects on disruptive behavior.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Conduct Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

7
Nervous System 4
Aggressive Behavior VERY_FREQUENT Aggressive behavior (HP:0000718)
Show evidence (2 references)
PMID:31249310 SUPPORT Human Clinical
"Conduct disorder (CD) is a common and highly impairing psychiatric disorder that usually emerges in childhood or adolescence and is characterized by severe antisocial and aggressive behaviour."
Nature Reviews Disease Primers review identifies severe antisocial and aggressive behaviour as the defining characterization.
PMID:25470696 SUPPORT Human Clinical
"The term "conduct problems" refers to a pattern of repetitive rule-breaking behavior, aggression, and disregard for others."
NEJM review defines conduct problems as including aggression.
Atypical Rule-Violating Behavior VERY_FREQUENT Atypical behavior (HP:0000708)
Show evidence (1 reference)
PMID:25470696 SUPPORT Human Clinical
"The term "conduct problems" refers to a pattern of repetitive rule-breaking behavior, aggression, and disregard for others."
NEJM review defines conduct problems as including repetitive rule-breaking behavior.
Irritability Irritability (HP:0000737)
Show evidence (1 reference)
PMID:25470696 SUPPORT Human Clinical
"The subgroup without callous–unemotional traits exhibits a different pattern, with atypically elevated threat-circuitry responsiveness"
NEJM review identifies heightened threat sensitivity and reactive aggression in the non-CU conduct disorder subgroup.
Neurocognitive Impairment Cognitive impairment (HP:0100543)
Show evidence (2 references)
PMID:31249310 SUPPORT Human Clinical
"CD is associated with neurocognitive impairments; smaller grey matter volume in limbic regions such as the amygdala, insula and orbitofrontal cortex, and functional abnormalities in overlapping brain circuits responsible for emotion processing, emotion regulation and reinforcement-based..."
Nature Reviews Disease Primers review comprehensively describes the neurocognitive impairments in CD.
PMID:26650724 SUPPORT Human Clinical
"Youths with CP had decreased GMV in the left amygdala (SDM estimate = -0.218; P < .001) (extending into anterior insula), right insula (SDM estimate = -0.174; P < .001) (extending ventrolaterally into the prefrontal cortex and inferiorly into the superior temporal gyrus), left medial superior..."
JAMA Psychiatry meta-analysis quantifies grey matter reductions in amygdala, insula, and frontal regions.
Other 3
Impulsivity Impulsivity (HP:0100710)
Show evidence (3 references)
PMID:25470696 SUPPORT Human Clinical
"These early signs involve aggressive tendencies, impulsivity, and failure to comply with requests"
NEJM review identifies impulsivity as an early sign of conduct disorder.
PMID:25470696 SUPPORT Human Clinical
"Persons who fail to learn how to make choices that lead to rewards rather than punishments are at high risk for impulsivity, frustration, and reactive aggression."
NEJM review links impulsivity to deficient decision-making circuitry.
PMID:31249310 SUPPORT Human Clinical
"CD is associated with neurocognitive impairments"
Nature Reviews Disease Primers review supports neurocognitive impairments including impulsivity-related deficits.
Deficient Empathy Impairment in personality functioning (HP:0031466)
Show evidence (2 references)
PMID:25470696 SUPPORT Human Clinical
"Deficient empathy shows a particularly selective association with conduct disorder accompanied by callous-unemotional traits."
NEJM review establishes deficient empathy as a selective neurocognitive dysfunction in CU-trait conduct disorder.
PMID:31249310 SUPPORT Human Clinical
"the presence or absence of callous-unemotional traits (deficits in empathy and guilt)"
Nature Reviews Disease Primers review characterizes CU traits as involving empathy and guilt deficits.
Reduced Cortisol Stress Reactivity Abnormality of the hypothalamus-pituitary axis (HP:0000864)
Show evidence (3 references)
PMID:31249310 SUPPORT Human Clinical
"Lower hypothalamic-pituitary-adrenal axis and autonomic reactivity to stress has also been reported."
Nature Reviews Disease Primers review confirms lower HPA axis and autonomic stress reactivity.
PMID:30155579 SUPPORT Human Clinical
"Cortisol hyporeactivity to stress is consistently reported in male antisocial populations, whereas no comparable data exist in females."
Systematic review confirms consistent cortisol hyporeactivity in male antisocial populations.
PMID:30155579 SUPPORT Human Clinical
"Severe antisocial behavior is associated with cortisol hyporeactivity to stress, and such hyporeactivity predicts poor treatment outcomes."
Cortisol hyporeactivity linked to poor treatment outcomes.
💊

Treatments

6
Parent management training
Action: parent management training Ontology label: behavioral counseling MAXO:0000077
Parent management training is an evidence-supported psychosocial treatment for children with clinical levels of disruptive behavior.
Target Phenotypes: Rule-violating behavior Aggressive behavior
Show evidence (1 reference)
DOI:10.1007/s10578-022-01367-y SUPPORT Human Clinical
"Results showed that PMT (g = 0.64 [95% CI 0.42, 0.86]) and PCIT (g = 1.22 [95% CI 0.75, 1.69]) were more effective than waiting-list (WL) in reducing parent-rated disruptive behavior"
Meta-analysis supports PMT for disruptive behavior symptoms relevant to conduct disorder.
Parent-child interaction therapy
Action: parent-child interaction therapy Ontology label: behavioral counseling MAXO:0000077
Parent-child interaction therapy is a parent-child psychosocial treatment with large waitlist-controlled effects in young children with disruptive behavior.
Target Phenotypes: Rule-violating behavior Aggressive behavior
Show evidence (1 reference)
DOI:10.1007/s10578-022-01367-y SUPPORT Human Clinical
"PCIT versus WL had larger effects in reducing disruptive behavior than PMT versus WL."
Meta-analysis supports PCIT for disruptive behavior symptoms.
Specialized modules for callous-unemotional traits
Action: specialized psychosocial treatment module Ontology label: behavioral counseling MAXO:0000077
Children with disruptive behavior disorders and callous-unemotional traits can improve with treatment, but higher severity supports specialized modules alongside parenting programs.
Target Phenotypes: Rule-violating behavior
Show evidence (1 reference)
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"DBD+CU children improve with treatment, but their greater DBD symptom severity requires specialized treatment modules that could be implemented alongside parenting programs."
Meta-analysis supports treatment response and specialized-module needs in DBD with CU traits.
Ziprasidone pharmacotherapy for severe aggression
Action: Pharmacotherapy NCIT:C15986
Agent: ziprasidone
Ziprasidone has been studied as adjunctive symptom-targeted pharmacotherapy for severe conduct and disruptive behavior disorders in older children and adolescents.
Target Phenotypes: Aggressive behavior
Show evidence (1 reference)
clinicaltrials:NCT00676429 SUPPORT Human Clinical
"To investigate and compare the efficacy, safety and tolerability of ziprasidone versus placebo in the treatment of conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) of older children and adolescents in an outpatient setting."
ClinicalTrials.gov record documents a Phase II ziprasidone trial for CD and related disruptive behavior disorders.
Methylphenidate pharmacotherapy for aggression
Action: Pharmacotherapy NCIT:C15986
Agent: methylphenidate
Psychostimulant therapy with methylphenidate can reduce aggression in youth with conduct disorder, including when ADHD is absent, but should be used judiciously with monitoring for adverse effects.
Target Phenotypes: Aggressive behavior
Show evidence (1 reference)
PMID:25470696 SUPPORT Human Clinical
"methylphenidate reduces aggression in youth with ADHD or with conduct disorder, even in the absence of ADHD."
NEJM review supports methylphenidate as symptom-targeted pharmacotherapy for aggression in conduct disorder.
Atypical antipsychotic pharmacotherapy for irritability and aggression
Action: Pharmacotherapy NCIT:C15986
Agent: risperidone aripiprazole
Atypical antipsychotics such as risperidone and aripiprazole can reduce irritability and aggression in children, with broader evidence in youth conduct problems but limitations from metabolic, neurologic, and sedating adverse effects.
Target Phenotypes: Aggressive behavior Irritability
Show evidence (2 references)
PMID:25470696 SUPPORT Human Clinical
"antipsychotic medications reduce irritability and aggression in children."
NEJM review supports antipsychotic medication effects on irritability and aggression.
PMID:25470696 SUPPORT Human Clinical
"The Food and Drug Administration (FDA) has approved two medications, risperidone and aripiprazole, for the treatment of irritability and aggression in autism."
NEJM review identifies risperidone and aripiprazole as the relevant atypical antipsychotics for pediatric irritability and aggression.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Conduct Disorder:

Overlapping Features ODD involves oppositional and defiant behavior without the more severe rights-violating conduct-disorder pattern.
Show evidence (1 reference)
clinicaltrials:NCT00676429 SUPPORT Human Clinical
"conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS)"
Trial record distinguishes CD from ODD and other disruptive behavior disorders.
Overlapping Features ADHD frequently co-occurs with CD and may drive impulsivity or functional impairment that needs separate assessment.
Show evidence (1 reference)
DOI:10.1186/s13034-024-00710-6 SUPPORT Human Clinical
"The rate of psychiatric comorbidity ranged from 69.7 to 86.1%, with attention-deficit/hyperactivity disorder being most common."
Real-world cohort supports ADHD as the commonest comorbidity.
Intermittent explosive disorder Not Yet Curated MONDO:0001521
Overlapping Features Intermittent explosive disorder can present with aggressive outbursts, but lacks the broader persistent pattern of rule violation, deceit, or rights violation required for CD.
Show evidence (1 reference)
DOI:10.1038/s41398-024-02870-7 PARTIAL Human Clinical
"Excessive and persistent aggressiveness is the most common behavioral problem that leads to psychiatric referrals among children."
Review supports aggression as a broad referral phenotype; the intermittent explosive disorder distinction is a clinical differential.
Antisocial personality disorder Not Yet Curated MONDO:0001164
Overlapping Features Antisocial personality disorder is an adult diagnosis related to persistent antisocial behavior and should not be substituted for pediatric conduct disorder in children.
Show evidence (1 reference)
DOI:10.1111/jcpp.13774 PARTIAL Human Clinical
"Children with callous‐unemotional (CU) traits are at high lifetime risk of antisocial behavior."
CU traits link childhood disruptive behavior to later antisocial outcomes, supporting adult antisocial behavior as a developmental differential and outcome consideration.
📊

Related Datasets

3
Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries DOI:10.1186/s13034-024-00710-6
Cross-sectional real-world healthcare data study comparing administrative prevalence, comorbidity, psychopharmacological treatment, and hospitalisation in youths with CD across Denmark, Germany, Norway, and the USA.
Homo sapiens
Conditions: conduct disorder psychiatric comorbidity
Findings
Administrative CD prevalence varied 31-fold across countries, and psychiatric comorbidity ranged from 69.7% to 86.1%.
Show evidence (1 reference)
DOI:10.1186/s13034-024-00710-6 SUPPORT Human Clinical
"The prevalence of diagnosed CD differed 31-fold between countries: 0.1% (Denmark), 0.3% (Norway), 1.1% (USA) and 3.1% (Germany), with a male/female ratio of 2.0–2.5:1."
Captures the main cross-country prevalence finding.
DOI:10.1186/s13034-024-00710-6
Show evidence (1 reference)
DOI:10.1186/s13034-024-00710-6 SUPPORT Human Clinical
"Cross-sectional observational study using healthcare data to identify children and adolescents (aged 0–19 years) with an ICD-10 code for CD within the calendar year 2018."
The abstract describes the real-world dataset and age range.
Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study DOI:10.1038/s41380-023-02383-7
Genotyped mother-father-child trio analysis testing transmission and genetic nurture effects on conduct problems at ages 8 and 14 in MoBa.
Homo sapiens n=31290
Conditions: conduct problems
Findings
Genetic transmission effects were detected for most tested PGS at age 8 and several at age 14, while genetic nurture effects were not detected for the selected PGS.
Show evidence (1 reference)
DOI:10.1038/s41380-023-02383-7 SUPPORT Human Clinical
"Conversely, we did not find genetic nurture effects for conduct problems using our selection of PGS."
Captures the contrast between transmission and genetic-nurture effects.
DOI:10.1038/s41380-023-02383-7
Show evidence (1 reference)
DOI:10.1038/s41380-023-02383-7 SUPPORT Human Clinical
"We used 31,290 genotyped mother-father-child trios from the Norwegian Mother, Father and Child Cohort Study (MoBa)"
The abstract provides the trio dataset size and source.
Treatment of childhood disruptive behavior disorders and <scp>callous‐unemotional</scp> traits: a systematic review and two multilevel <scp>meta‐analyses</scp> DOI:10.1111/jcpp.13774
Systematic review and multilevel meta-analyses of treatments for childhood disruptive behavior disorders with and without callous-unemotional traits.
Homo sapiens n=9405
Conditions: disruptive behavior disorder callous-unemotional traits
Findings
Treatment reduced disruptive behavior symptoms in both DBD+CU and DBD-only children, but DBD+CU children had greater symptom severity.
Show evidence (1 reference)
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"treatment was associated with similar reductions in DBD symptoms for DBD+CU ( SMD = 1.08, 95% CI = 0.45, 1.72) and DBD‐only ( SMD = 1.01, 95% CI = 0.38, 1.64)."
Captures the primary treatment-effect comparison by CU-trait status.
DOI:10.1111/jcpp.13774
Show evidence (1 reference)
DOI:10.1111/jcpp.13774 SUPPORT Human Clinical
"Sixty studies with 9,405 participants were included"
The abstract reports the evidence base for the treatment meta-analyses.
🔬

Clinical Trials

3
NCT00676429 PHASE_II COMPLETED
Placebo-controlled randomized double-blind trial of ziprasidone for severe conduct and other disruptive behavior disorders in older children and adolescents.
Target Phenotypes: Aggressive behavior
Show evidence (1 reference)
clinicaltrials:NCT00676429 SUPPORT Human Clinical
"To investigate and compare the efficacy, safety and tolerability of ziprasidone versus placebo in the treatment of conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) of older children and adolescents in an outpatient setting."
ClinicalTrials.gov record documents a completed ziprasidone trial for CD and related disruptive behavior disorders.
NCT02828969 NOT_APPLICABLE UNKNOWN
Observational trajectory study of children and adolescents with disruptive behavior admitted to pediatric and psychiatric emergency settings.
Target Phenotypes: Rule-violating behavior
Show evidence (1 reference)
clinicaltrials:NCT02828969 SUPPORT Human Clinical
"The Trajectories project is designed to describe children and adolescents with disruptive behaviors, their care management and to follow their life trajectory and psychiatric evolution after admission to emergency rooms."
ClinicalTrials.gov record documents a clinical trajectory study in disruptive behavior emergencies.
NCT07091721 NOT_APPLICABLE RECRUITING
Randomized controlled trial of mentalization-based support for aggressive and violent behavior in young people referred to forensic child and adolescent mental health services.
Target Phenotypes: Aggressive behavior
Show evidence (1 reference)
clinicaltrials:NCT07091721 SUPPORT Human Clinical
"This research involves doing a randomised controlled trial. This means half the young people will get the usual support from FCAMHS, and half will get the usual support plus the new support."
ClinicalTrials.gov record documents a currently recruiting RCT for aggressive and violent behavior support.
{ }

Source YAML

click to show
name: Conduct Disorder
creation_date: "2026-04-24T20:56:38Z"
updated_date: "2026-05-02T00:00:00Z"
category: Psychiatric
description: >-
  Conduct disorder is a disruptive behavior disorder characterized by a
  repetitive and persistent pattern of aggressive, antisocial, deceitful, or
  rule-violating behavior that infringes the rights of others or
  age-appropriate norms.
disease_term:
  preferred_term: conduct disorder
  term:
    id: MONDO:0005352
    label: conduct disorder
parents:
- Mental Health Disorder
has_subtypes:
- name: Childhood-onset conduct disorder
  classification: DSM-5 age-of-onset specifier
  description: >-
    Conduct-disorder subtype where at least one conduct-disorder symptom is
    present before age 10 years; this specifier is clinically important for
    prognosis and service planning.
  evidence:
  - reference: clinicaltrials:NCT02828969
    reference_title: Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Trajectories project is designed to describe children and adolescents
      with disruptive behaviors, their care management and to follow their life
      trajectory and psychiatric evolution after admission to emergency rooms.
    explanation: >-
      The trajectory study supports child and adolescent CD-spectrum
      presentations; the age-of-onset threshold is a DSM clinical specifier.
- name: Adolescent-onset conduct disorder
  classification: DSM-5 age-of-onset specifier
  description: >-
    Conduct-disorder subtype where conduct-disorder symptoms emerge in
    adolescence without symptoms before age 10 years.
  evidence:
  - reference: clinicaltrials:NCT02828969
    reference_title: Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Trajectories project is designed to describe children and adolescents
      with disruptive behaviors, their care management and to follow their life
      trajectory and psychiatric evolution after admission to emergency rooms.
    explanation: >-
      The trajectory study supports adolescent CD-spectrum presentations; the
      age-of-onset threshold is a DSM clinical specifier.
- name: Conduct disorder with limited prosocial emotions
  classification: DSM-5 specifier
  description: >-
    Conduct-disorder specifier marked by persistent callous-unemotional traits
    such as low remorse, low empathy, shallow affect, or limited concern about
    performance; this subgroup has greater antisocial risk and symptom severity.
  evidence:
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with callous‐unemotional (CU) traits are at high lifetime risk
      of antisocial behavior.
    explanation: >-
      Meta-analysis background supports CU traits as a clinically meaningful
      limited-prosocial-emotions specifier.
prevalence:
- population: community children and adolescents
  percentage: 3
  notes: >-
    CD affects approximately 3% of school-aged children, with a 2:1 male to
    female ratio.
  evidence:
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CD affects ~3% of school-aged children and is twice as prevalent in
      males than in females.
    explanation: >-
      Nature Reviews Disease Primers review provides prevalence and sex ratio.
  - reference: DOI:10.1186/s13034-024-00710-6
    reference_title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conduct disorders (CD) are among the most frequent psychiatric disorders
      in children and adolescents, with an estimated worldwide prevalence in
      the community of 2–4%.
    explanation: >-
      Real-world data study introduction provides an estimated community
      prevalence range.
pathophysiology:
- name: Intergenerational Polygenic Liability
  description: >-
    Conduct problems show polygenic transmission from parental characteristics
    to child conduct problems, supporting a heritable liability component
    embedded in family development.
  downstream:
  - target: Childhood Aggression Genetic Architecture
    description: >-
      Polygenic transmission is represented upstream of aggression-related
      genetic liability and behavioral outcomes.
  evidence:
  - reference: DOI:10.1038/s41380-023-02383-7
    reference_title: "Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aetiology of conduct problems involves a combination of genetic and
      environmental factors, many of which are inherently linked to parental
      characteristics given parents’ central role in children’s lives across
      development.
    explanation: >-
      Trio study frames conduct problems as genetically and environmentally
      influenced.
  - reference: DOI:10.1038/s41380-023-02383-7
    reference_title: "Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found significant genetic transmission effects on conduct problems
      for 12 out of 13 PGS at age 8 years
    explanation: >-
      The MoBa trio analysis supports genetic transmission effects.
- name: Childhood Aggression Genetic Architecture
  description: >-
    Persistent aggression, a central conduct-disorder behavior domain, has
    substantial genetic contribution, but candidate-gene and GxE findings are
    heterogeneous and not ready for deterministic interpretation.
  downstream:
  - target: Persistent Antisocial and Aggressive Behavior
    description: >-
      Aggression-related genetic liability is represented upstream of the
      clinical aggressive-behavior phenotype.
  evidence:
  - reference: DOI:10.1038/s41398-024-02870-7
    reference_title: "Genetics of child aggression, a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While half of the variance in childhood aggression is attributed to
      genetic factors, the biological mechanism and the interplay between genes
      and environment that results in aggression remains elusive.
    explanation: >-
      Systematic review supports genetic contribution but emphasizes unresolved
      mechanisms.
  - reference: DOI:10.1038/s41398-024-02870-7
    reference_title: "Genetics of child aggression, a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      investigation of candidate genes, especially of MAOA (17 studies), DRD4
      (13 studies), and COMT (12 studies) continue to dominate the field
    explanation: >-
      Review identifies commonly studied aggression candidate genes.
- name: Amygdala-Mediated Empathy Deficit
  description: >-
    In the conduct-disorder subgroup with callous-unemotional traits, deficient
    empathy is linked to reduced amygdala responses to fearful facial
    expressions and impaired recognition of distress in others.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  downstream:
  - target: Callous-Unemotional Trait Severity
    description: >-
      Amygdala-mediated empathy impairment is represented as an upstream
      neurocognitive mechanism for the callous-unemotional conduct-disorder
      subgroup.
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deficient empathy shows a particularly selective association with conduct
      disorder accompanied by callous–unemotional traits.
    explanation: >-
      NEJM review identifies deficient empathy as selective for the
      callous-unemotional conduct-disorder subgroup.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deficient empathy is related to amygdala dysfunction.
    explanation: >-
      NEJM review links the deficient-empathy mechanism to amygdala dysfunction.
- name: Threat-Circuit Hypersensitivity
  description: >-
    Youth with conduct disorder who do not have callous-unemotional traits can
    show heightened threat-circuit responsiveness across the
    amygdala-hypothalamus-periaqueductal gray pathway, increasing risk of
    hostile attribution, frustration sensitivity, and reactive aggression.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  - preferred_term: hypothalamus
    term:
      id: UBERON:0001898
      label: hypothalamus
  - preferred_term: central gray substance of midbrain
    term:
      id: UBERON:0003040
      label: central gray substance of midbrain
  downstream:
  - target: Persistent Antisocial and Aggressive Behavior
    description: >-
      Threat-circuit hypersensitivity is modeled as a circuit-level contributor
      to reactive aggression in the non-callous-unemotional subgroup.
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The subgroup without callous–unemotional traits exhibits a different
      pattern, with atypically elevated threat-circuitry responsiveness
    explanation: >-
      NEJM review identifies heightened threat-circuit responsiveness in the
      conduct-disorder subgroup without callous-unemotional traits.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the amygdala is part of a circuit, encompassing the hypothalamus and
      periaqueductal gray matter, that mediates graded responses to threats
    explanation: >-
      NEJM review defines the threat-response circuit containing amygdala,
      hypothalamus, and periaqueductal gray matter.
- name: Striato-vmPFC Decision-Making Deficit
  description: >-
    Conduct problems are associated with impaired reinforcement-based
    decision-making, including deficient negative-prediction-error signaling and
    deficient recruitment of the striatum and ventromedial prefrontal cortex.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  downstream:
  - target: Persistent Antisocial and Aggressive Behavior
    description: >-
      Deficient reward-punishment learning is modeled upstream of impulsivity,
      frustration, and reactive aggression.
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Persons who fail to learn how to make choices that lead to rewards rather
      than punishments are at high risk for impulsivity, frustration, and
      reactive aggression.
    explanation: >-
      NEJM review links deficient reward-punishment learning to impulsivity,
      frustration, and reactive aggression.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      youth with conduct problems show deficits in negative-prediction-error
      signaling, manifested by deficient recruitment of the striatum and
      ventromedial prefrontal cortex.
    explanation: >-
      NEJM review identifies striatal and ventromedial prefrontal recruitment
      deficits during reinforcement learning.
- name: Persistent Antisocial and Aggressive Behavior
  description: >-
    The core behavioral mechanism is persistent violation of rules and rights,
    often expressed through aggressive, antisocial, or defiant behavior that
    requires social, clinical, and sometimes justice-system response.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  evidence:
  - reference: clinicaltrials:NCT02828969
    reference_title: Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conduct disorders are defined as "repetitive and persistent pattern of
      behavior in which the basic rights of others or major age-appropriate
      norms are violated".
    explanation: >-
      ClinicalTrials.gov trajectory study provides a concise conduct-disorder
      behavioral definition.
  - reference: clinicaltrials:NCT00676429
    reference_title: Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main characteristic of these disorders is a repetitive and persistent
      pattern of antisocial, aggressive or defiant behavior that involves major
      violations of age-appropriate expectations or norms.
    explanation: >-
      Trial background supports the aggressive and antisocial behavior node.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Youth conduct problems are predictive of an increased risk of substance
      abuse, criminal behavior, and educational disruption
    explanation: >-
      NEJM review documents the long-term antisocial outcomes of conduct
      problems.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antisocial personality disorder, which has a particularly poor prognosis,
      develops in slightly less than 50% of patients with conduct disorder
    explanation: >-
      NEJM review provides the rate of progression to antisocial personality
      disorder.
- name: Callous-Unemotional Trait Severity
  description: >-
    Callous-unemotional traits identify a clinically important disruptive
    behavior subgroup with higher antisocial risk and greater symptom severity,
    while still showing improvement in disruptive behavior symptoms with
    treatment.
  downstream:
  - target: Persistent Antisocial and Aggressive Behavior
    description: >-
      CU traits are modeled as a severity modifier that can intensify or
      stabilize antisocial behavior trajectories.
  evidence:
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with callous‐unemotional (CU) traits are at high lifetime risk
      of antisocial behavior.
    explanation: >-
      Meta-analysis background supports CU traits as a risk/severity dimension.
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DBD+CU children improve with treatment, but their greater DBD symptom
      severity requires specialized treatment modules that could be implemented
      alongside parenting programs.
    explanation: >-
      Meta-analysis conclusion supports CU traits as a clinically relevant
      modifier of severity and treatment planning.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Callous–unemotional traits, which occur in fewer than half of young
      persons with conduct disorder, identify a subgroup with distinctive
      clinical features and neurocognitive perturbations.
    explanation: >-
      NEJM review establishes CU traits as identifying a distinctive subgroup
      with unique neurocognitive features.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As compared with youth with conduct disorder who show remorse, empathy,
      and concern about school performance, those with callous–unemotional
      traits have a poorer prognosis and treatment response.
    explanation: >-
      NEJM review confirms poorer prognosis in CU-trait subgroup.
- name: Psychosocial Intervention Response
  description: >-
    Evidence-based parent-management and parent-child interventions reduce
    disruptive behavior, indicating that family and social-learning mechanisms
    are modifiable downstream contributors.
  downstream:
  - target: Persistent Antisocial and Aggressive Behavior
    description: >-
      Psychosocial interventions are modeled as modulating the persistent
      disruptive and aggressive behavior mechanism.
  evidence:
  - reference: DOI:10.1007/s10578-022-01367-y
    reference_title: "The Efficacy of Parent Management Training With or Without Involving the Child in the Treatment Among Children with Clinical Levels of Disruptive Behavior: A Meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Results showed that PMT (g = 0.64 [95% CI 0.42, 0.86]) and PCIT
      (g = 1.22 [95% CI 0.75, 1.69]) were more effective than waiting-list
      (WL) in reducing parent-rated disruptive behavior
    explanation: >-
      Meta-analysis supports parent-focused intervention effects on disruptive
      behavior.
phenotypes:
- name: Aggressive Behavior
  category: Behavioral
  description: >-
    Aggression is a core conduct-disorder behavior domain, encompassing physical
    aggression toward people or animals, destruction of property, and
    confrontational antisocial acts.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conduct disorder (CD) is a common and highly impairing psychiatric
      disorder that usually emerges in childhood or adolescence and is
      characterized by severe antisocial and aggressive behaviour.
    explanation: >-
      Nature Reviews Disease Primers review identifies severe antisocial and
      aggressive behaviour as the defining characterization.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The term "conduct problems" refers to a pattern of repetitive
      rule-breaking behavior, aggression, and disregard for others.
    explanation: >-
      NEJM review defines conduct problems as including aggression.
- name: Atypical Rule-Violating Behavior
  category: Behavioral
  description: >-
    Persistent rule-violating, deceitful, or rights-violating behavior is a
    defining conduct-disorder presentation that infringes on the rights of
    others or major age-appropriate norms.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Rule-violating behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The term "conduct problems" refers to a pattern of repetitive
      rule-breaking behavior, aggression, and disregard for others.
    explanation: >-
      NEJM review defines conduct problems as including repetitive
      rule-breaking behavior.
- name: Impulsivity
  category: Behavioral
  description: >-
    Impulsive behavior is a prominent feature of conduct disorder, contributing
    to poor decision-making, frustration, and reactive aggression. Deficits
    in reinforcement-based decision-making are consistently found.
  phenotype_term:
    preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These early signs involve aggressive tendencies, impulsivity, and failure
      to comply with requests
    explanation: >-
      NEJM review identifies impulsivity as an early sign of conduct disorder.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Persons who fail to learn how to make choices that lead to rewards rather
      than punishments are at high risk for impulsivity, frustration, and
      reactive aggression.
    explanation: >-
      NEJM review links impulsivity to deficient decision-making circuitry.
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CD is associated with neurocognitive impairments
    explanation: >-
      Nature Reviews Disease Primers review supports neurocognitive impairments
      including impulsivity-related deficits.
- name: Deficient Empathy
  category: Behavioral
  description: >-
    Deficient empathy is selectively associated with the callous-unemotional
    traits subgroup of conduct disorder. It manifests as minimal emotional
    responses and impaired ability to recognize distress in others, and is
    related to amygdala dysfunction.
  phenotype_term:
    preferred_term: Deficient empathy
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deficient empathy shows a particularly selective association with conduct
      disorder accompanied by callous-unemotional traits.
    explanation: >-
      NEJM review establishes deficient empathy as a selective neurocognitive
      dysfunction in CU-trait conduct disorder.
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the presence or absence of callous-unemotional traits (deficits in
      empathy and guilt)
    explanation: >-
      Nature Reviews Disease Primers review characterizes CU traits as
      involving empathy and guilt deficits.
- name: Irritability
  category: Behavioral
  description: >-
    Irritability and emotional dysregulation can occur in disruptive behavior
    presentations. Youth without callous-unemotional traits may show heightened
    threat sensitivity and reactive aggression in response to frustration or
    threat.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The subgroup without callous–unemotional traits exhibits a different
      pattern, with atypically elevated threat-circuitry responsiveness
    explanation: >-
      NEJM review identifies heightened threat sensitivity and reactive
      aggression in the non-CU conduct disorder subgroup.
- name: Neurocognitive Impairment
  category: Neurological
  description: >-
    Conduct disorder is associated with neurocognitive impairments including
    deficits in emotion processing, emotion regulation, and
    reinforcement-based decision-making, with functional abnormalities in
    corresponding brain circuits.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CD is associated with neurocognitive impairments; smaller grey matter
      volume in limbic regions such as the amygdala, insula and orbitofrontal
      cortex, and functional abnormalities in overlapping brain circuits
      responsible for emotion processing, emotion regulation and
      reinforcement-based decision-making have been reported.
    explanation: >-
      Nature Reviews Disease Primers review comprehensively describes the
      neurocognitive impairments in CD.
  - reference: PMID:26650724
    reference_title: "Cortical and Subcortical Gray Matter Volume in Youths With Conduct Problems: A Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Youths with CP had decreased GMV in the left amygdala (SDM
      estimate = -0.218; P < .001) (extending into anterior insula), right
      insula (SDM estimate = -0.174; P < .001) (extending ventrolaterally into
      the prefrontal cortex and inferiorly into the superior temporal gyrus),
      left medial superior frontal gyrus (SDM estimate = -0.163; P = .001)
      (extending into the right anterior cingulate cortex), and left fusiform
      gyrus (SDM estimate = -0.146; P = .003).
    explanation: >-
      JAMA Psychiatry meta-analysis quantifies grey matter reductions in
      amygdala, insula, and frontal regions.
- name: Reduced Cortisol Stress Reactivity
  category: Endocrine
  description: >-
    Lower hypothalamic-pituitary-adrenal axis and autonomic reactivity to
    stress has been reported in conduct disorder, with cortisol
    hyporeactivity consistently found in male antisocial populations and
    associated with poor treatment outcomes.
  phenotype_term:
    preferred_term: Abnormality of the hypothalamus-pituitary axis
    term:
      id: HP:0000864
      label: Abnormality of the hypothalamus-pituitary axis
  evidence:
  - reference: PMID:31249310
    reference_title: Conduct disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lower hypothalamic-pituitary-adrenal axis and autonomic reactivity to
      stress has also been reported.
    explanation: >-
      Nature Reviews Disease Primers review confirms lower HPA axis and
      autonomic stress reactivity.
  - reference: PMID:30155579
    reference_title: Hypothalamic-Pituitary-Adrenal Axis Function in Children and Adults with Severe Antisocial Behavior and the Impact of Early Adversity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cortisol hyporeactivity to stress is consistently reported in male
      antisocial populations, whereas no comparable data exist in females.
    explanation: >-
      Systematic review confirms consistent cortisol hyporeactivity in male
      antisocial populations.
  - reference: PMID:30155579
    reference_title: Hypothalamic-Pituitary-Adrenal Axis Function in Children and Adults with Severe Antisocial Behavior and the Impact of Early Adversity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Severe antisocial behavior is associated with cortisol hyporeactivity to
      stress, and such hyporeactivity predicts poor treatment outcomes.
    explanation: >-
      Cortisol hyporeactivity linked to poor treatment outcomes.
diagnosis:
- name: Clinical Behavioral Assessment
  presence: >-
    Diagnosis is based on persistent behavioral criteria, impairment, age of
    onset, severity, limited-prosocial-emotions traits, comorbidities, and
    exclusion of alternative explanations.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: clinicaltrials:NCT02828969
    reference_title: Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conduct disorders are defined as "repetitive and persistent pattern of
      behavior in which the basic rights of others or major age-appropriate
      norms are violated".
    explanation: >-
      The record supports diagnosis by behavioral pattern.
- name: Comorbidity and Service-Use Assessment
  presence: >-
    Assessment includes ADHD and other psychiatric comorbidities, medication
    exposure, hospitalisation, emergency presentation, and social-care context.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: DOI:10.1186/s13034-024-00710-6
    reference_title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Within each country’s study population, the prevalence of CD,
      psychiatric comorbidity, psychopharmacological treatment, and psychiatric
      hospitalisation was calculated.
    explanation: >-
      Real-world study supports assessing comorbidity, treatment, and
      hospitalisation context.
- name: Biomarkers remain investigational
  presence: >-
    Biomarkers are not established for routine diagnosis; clinical diagnosis
    remains behavioral and contextual.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: DOI:10.1002/wps.21037
    reference_title: "Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other important metrics to assess the validity of a candidate biomarker,
      such as positive predictive value and negative predictive value, were
      infrequently reported.
    explanation: >-
      Biomarker review supports the need for clinical rather than biomarker-only
      diagnosis.
differential_diagnoses:
- name: Oppositional defiant disorder
  description: >-
    ODD involves oppositional and defiant behavior without the more severe
    rights-violating conduct-disorder pattern.
  disease_term:
    preferred_term: oppositional defiant disorder
    term:
      id: MONDO:0000495
      label: oppositional defiant disorder
  evidence:
  - reference: clinicaltrials:NCT00676429
    reference_title: Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive
      behavior disorder not otherwise specified (DBD-NOS)
    explanation: >-
      Trial record distinguishes CD from ODD and other disruptive behavior
      disorders.
- name: Attention deficit-hyperactivity disorder
  description: >-
    ADHD frequently co-occurs with CD and may drive impulsivity or functional
    impairment that needs separate assessment.
  disease_term:
    preferred_term: attention deficit-hyperactivity disorder
    term:
      id: MONDO:0007743
      label: attention deficit-hyperactivity disorder
  evidence:
  - reference: DOI:10.1186/s13034-024-00710-6
    reference_title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rate of psychiatric comorbidity ranged from 69.7 to 86.1%, with
      attention-deficit/hyperactivity disorder being most common.
    explanation: >-
      Real-world cohort supports ADHD as the commonest comorbidity.
- name: Intermittent explosive disorder
  description: >-
    Intermittent explosive disorder can present with aggressive outbursts, but
    lacks the broader persistent pattern of rule violation, deceit, or rights
    violation required for CD.
  disease_term:
    preferred_term: intermittent explosive disorder
    term:
      id: MONDO:0001521
      label: intermittent explosive disorder
  evidence:
  - reference: DOI:10.1038/s41398-024-02870-7
    reference_title: "Genetics of child aggression, a systematic review"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Excessive and persistent aggressiveness is the most common behavioral
      problem that leads to psychiatric referrals among children.
    explanation: >-
      Review supports aggression as a broad referral phenotype; the
      intermittent explosive disorder distinction is a clinical differential.
- name: Antisocial personality disorder
  description: >-
    Antisocial personality disorder is an adult diagnosis related to
    persistent antisocial behavior and should not be substituted for pediatric
    conduct disorder in children.
  disease_term:
    preferred_term: antisocial personality disorder
    term:
      id: MONDO:0001164
      label: antisocial personality disorder
  evidence:
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with callous‐unemotional (CU) traits are at high lifetime risk
      of antisocial behavior.
    explanation: >-
      CU traits link childhood disruptive behavior to later antisocial
      outcomes, supporting adult antisocial behavior as a developmental
      differential and outcome consideration.
treatments:
- name: Parent management training
  description: >-
    Parent management training is an evidence-supported psychosocial treatment
    for children with clinical levels of disruptive behavior.
  treatment_term:
    preferred_term: parent management training
    term:
      id: MAXO:0000077
      label: behavioral counseling
  target_phenotypes:
  - preferred_term: Rule-violating behavior
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: DOI:10.1007/s10578-022-01367-y
    reference_title: "The Efficacy of Parent Management Training With or Without Involving the Child in the Treatment Among Children with Clinical Levels of Disruptive Behavior: A Meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Results showed that PMT (g = 0.64 [95% CI 0.42, 0.86]) and PCIT
      (g = 1.22 [95% CI 0.75, 1.69]) were more effective than waiting-list
      (WL) in reducing parent-rated disruptive behavior
    explanation: >-
      Meta-analysis supports PMT for disruptive behavior symptoms relevant to
      conduct disorder.
- name: Parent-child interaction therapy
  description: >-
    Parent-child interaction therapy is a parent-child psychosocial treatment
    with large waitlist-controlled effects in young children with disruptive
    behavior.
  treatment_term:
    preferred_term: parent-child interaction therapy
    term:
      id: MAXO:0000077
      label: behavioral counseling
  target_phenotypes:
  - preferred_term: Rule-violating behavior
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: DOI:10.1007/s10578-022-01367-y
    reference_title: "The Efficacy of Parent Management Training With or Without Involving the Child in the Treatment Among Children with Clinical Levels of Disruptive Behavior: A Meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PCIT versus WL had larger effects in reducing disruptive behavior than
      PMT versus WL.
    explanation: >-
      Meta-analysis supports PCIT for disruptive behavior symptoms.
- name: Specialized modules for callous-unemotional traits
  description: >-
    Children with disruptive behavior disorders and callous-unemotional traits
    can improve with treatment, but higher severity supports specialized
    modules alongside parenting programs.
  treatment_term:
    preferred_term: specialized psychosocial treatment module
    term:
      id: MAXO:0000077
      label: behavioral counseling
  target_phenotypes:
  - preferred_term: Rule-violating behavior
  evidence:
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DBD+CU children improve with treatment, but their greater DBD symptom
      severity requires specialized treatment modules that could be implemented
      alongside parenting programs.
    explanation: >-
      Meta-analysis supports treatment response and specialized-module needs in
      DBD with CU traits.
- name: Ziprasidone pharmacotherapy for severe aggression
  description: >-
    Ziprasidone has been studied as adjunctive symptom-targeted pharmacotherapy
    for severe conduct and disruptive behavior disorders in older children and
    adolescents.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ziprasidone
      term:
        id: CHEBI:10119
        label: ziprasidone
  target_phenotypes:
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: clinicaltrials:NCT00676429
    reference_title: Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To investigate and compare the efficacy, safety and tolerability of
      ziprasidone versus placebo in the treatment of conduct disorder (CD),
      oppositional defiant disorder (ODD) and disruptive behavior disorder not
      otherwise specified (DBD-NOS) of older children and adolescents in an
      outpatient setting.
    explanation: >-
      ClinicalTrials.gov record documents a Phase II ziprasidone trial for CD
      and related disruptive behavior disorders.
- name: Methylphenidate pharmacotherapy for aggression
  description: >-
    Psychostimulant therapy with methylphenidate can reduce aggression in youth
    with conduct disorder, including when ADHD is absent, but should be used
    judiciously with monitoring for adverse effects.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methylphenidate
      term:
        id: CHEBI:6887
        label: methylphenidate
  target_phenotypes:
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      methylphenidate reduces aggression in youth with ADHD or with conduct
      disorder, even in the absence of ADHD.
    explanation: >-
      NEJM review supports methylphenidate as symptom-targeted pharmacotherapy
      for aggression in conduct disorder.
- name: Atypical antipsychotic pharmacotherapy for irritability and aggression
  description: >-
    Atypical antipsychotics such as risperidone and aripiprazole can reduce
    irritability and aggression in children, with broader evidence in youth
    conduct problems but limitations from metabolic, neurologic, and sedating
    adverse effects.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: risperidone
      term:
        id: CHEBI:8871
        label: risperidone
    - preferred_term: aripiprazole
      term:
        id: CHEBI:31236
        label: aripiprazole
  target_phenotypes:
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  - preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      antipsychotic medications reduce irritability and aggression in children.
    explanation: >-
      NEJM review supports antipsychotic medication effects on irritability and
      aggression.
  - reference: PMID:25470696
    reference_title: Conduct disorder and callous-unemotional traits in youth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Food and Drug Administration (FDA) has approved two medications,
      risperidone and aripiprazole, for the treatment of irritability and
      aggression in autism.
    explanation: >-
      NEJM review identifies risperidone and aripiprazole as the relevant
      atypical antipsychotics for pediatric irritability and aggression.
clinical_trials:
- name: NCT00676429
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Placebo-controlled randomized double-blind trial of ziprasidone for severe
    conduct and other disruptive behavior disorders in older children and
    adolescents.
  target_phenotypes:
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: clinicaltrials:NCT00676429
    reference_title: Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To investigate and compare the efficacy, safety and tolerability of
      ziprasidone versus placebo in the treatment of conduct disorder (CD),
      oppositional defiant disorder (ODD) and disruptive behavior disorder not
      otherwise specified (DBD-NOS) of older children and adolescents in an
      outpatient setting.
    explanation: >-
      ClinicalTrials.gov record documents a completed ziprasidone trial for CD
      and related disruptive behavior disorders.
- name: NCT02828969
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Observational trajectory study of children and adolescents with disruptive
    behavior admitted to pediatric and psychiatric emergency settings.
  target_phenotypes:
  - preferred_term: Rule-violating behavior
  evidence:
  - reference: clinicaltrials:NCT02828969
    reference_title: Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Trajectories project is designed to describe children and adolescents
      with disruptive behaviors, their care management and to follow their life
      trajectory and psychiatric evolution after admission to emergency rooms.
    explanation: >-
      ClinicalTrials.gov record documents a clinical trajectory study in
      disruptive behavior emergencies.
- name: NCT07091721
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Randomized controlled trial of mentalization-based support for aggressive
    and violent behavior in young people referred to forensic child and
    adolescent mental health services.
  target_phenotypes:
  - preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: clinicaltrials:NCT07091721
    reference_title: "The Mentalization Intervention for Children and Adolescents (MICA) Study: A Randomised Controlled Trial of Support for Aggressive and Violent Behaviour Via Forensic Child and Adolescent Mental Health Services (FCAMHS)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This research involves doing a randomised controlled trial. This means
      half the young people will get the usual support from FCAMHS, and half
      will get the usual support plus the new support.
    explanation: >-
      ClinicalTrials.gov record documents a currently recruiting RCT for
      aggressive and violent behavior support.
datasets:
- accession: DOI:10.1186/s13034-024-00710-6
  title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
  description: >-
    Cross-sectional real-world healthcare data study comparing administrative
    prevalence, comorbidity, psychopharmacological treatment, and
    hospitalisation in youths with CD across Denmark, Germany, Norway, and the
    USA.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  conditions:
  - conduct disorder
  - psychiatric comorbidity
  publication: DOI:10.1186/s13034-024-00710-6
  evidence:
  - reference: DOI:10.1186/s13034-024-00710-6
    reference_title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cross-sectional observational study using healthcare data to identify
      children and adolescents (aged 0–19 years) with an ICD-10 code for CD
      within the calendar year 2018.
    explanation: >-
      The abstract describes the real-world dataset and age range.
  findings:
  - statement: Administrative CD prevalence varied 31-fold across countries, and psychiatric comorbidity ranged from 69.7% to 86.1%.
    evidence:
    - reference: DOI:10.1186/s13034-024-00710-6
      reference_title: "Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The prevalence of diagnosed CD differed 31-fold between countries:
        0.1% (Denmark), 0.3% (Norway), 1.1% (USA) and 3.1% (Germany), with a
        male/female ratio of 2.0–2.5:1.
      explanation: >-
        Captures the main cross-country prevalence finding.
- accession: DOI:10.1038/s41380-023-02383-7
  title: "Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study"
  description: >-
    Genotyped mother-father-child trio analysis testing transmission and
    genetic nurture effects on conduct problems at ages 8 and 14 in MoBa.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 31290
  conditions:
  - conduct problems
  publication: DOI:10.1038/s41380-023-02383-7
  evidence:
  - reference: DOI:10.1038/s41380-023-02383-7
    reference_title: "Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We used 31,290 genotyped mother-father-child trios from the Norwegian
      Mother, Father and Child Cohort Study (MoBa)
    explanation: >-
      The abstract provides the trio dataset size and source.
  findings:
  - statement: Genetic transmission effects were detected for most tested PGS at age 8 and several at age 14, while genetic nurture effects were not detected for the selected PGS.
    evidence:
    - reference: DOI:10.1038/s41380-023-02383-7
      reference_title: "Examining intergenerational risk factors for conduct problems using polygenic scores in the Norwegian Mother, Father and Child Cohort Study"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Conversely, we did not find genetic nurture effects for conduct
        problems using our selection of PGS.
      explanation: >-
        Captures the contrast between transmission and genetic-nurture effects.
- accession: DOI:10.1111/jcpp.13774
  title: "Treatment of childhood disruptive behavior disorders and <scp>callous‐unemotional</scp> traits: a systematic review and two multilevel <scp>meta‐analyses</scp>"
  description: >-
    Systematic review and multilevel meta-analyses of treatments for childhood
    disruptive behavior disorders with and without callous-unemotional traits.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 9405
  conditions:
  - disruptive behavior disorder
  - callous-unemotional traits
  publication: DOI:10.1111/jcpp.13774
  evidence:
  - reference: DOI:10.1111/jcpp.13774
    reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sixty studies with 9,405 participants were included
    explanation: >-
      The abstract reports the evidence base for the treatment meta-analyses.
  findings:
  - statement: Treatment reduced disruptive behavior symptoms in both DBD+CU and DBD-only children, but DBD+CU children had greater symptom severity.
    evidence:
    - reference: DOI:10.1111/jcpp.13774
      reference_title: "Treatment of childhood disruptive behavior disorders and\n                    <scp>callous‐unemotional</scp>\n                    traits: a systematic review and two multilevel\n                    <scp>meta‐analyses</scp>"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        treatment was associated with similar reductions in DBD symptoms for
        DBD+CU ( SMD  = 1.08, 95% CI = 0.45, 1.72) and DBD‐only ( SMD  =
        1.01, 95% CI = 0.38, 1.64).
      explanation: >-
        Captures the primary treatment-effect comparison by CU-trait status.
notes: >-
  Pathophysiology entries are separated into polygenic transmission, aggression
  genetics, persistent antisocial behavior, callous-unemotional trait severity,
  biomarker limitations, and psychosocial intervention response so downstream
  relationships remain granular.
📚

References & Deep Research

Deep Research

1
Falcon
Disease Characteristics Research Template
Edison Scientific Literature 54 citations 2026-04-24T17:16:26.109032

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Conduct Disorder
  • MONDO ID: (if available)
  • Category: Psychiatric

Research Objectives

Please provide a comprehensive research report on Conduct Disorder covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.


1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Conduct Disorder (CD): Disease Characteristics Research Report (Psychiatric)

Target disease

  • Disease name: Conduct Disorder (CD) (DSM-5/DSM-5-TR terminology) (masi2023contemporarydiagnosisand pages 1-5)
  • ICD-11 closest entity: Conduct-dissocial disorder (ICD-11 code 6C91) (ruotsalainen2022childhoodpsychopathyin pages 18-21)
  • MONDO ID: Not identified from the retrieved sources in this run (no MONDO mapping document retrieved).

Executive summary

Conduct disorder is a childhood/adolescent-onset psychiatric disorder defined by a persistent pattern of behaviors violating the rights of others and major societal norms/rules, spanning aggression, property destruction, deceit/theft, and serious rule violations (masi2023contemporarydiagnosisand pages 1-5, ruotsalainen2022childhoodpsychopathyin pages 38-43). Modern classification emphasizes clinically meaningful heterogeneity via specifiers for age of onset and limited prosocial emotions (LPE)/callous-unemotional (CU) traits, which are associated with more severe antisocial trajectories and may moderate treatment response (masi2023contemporarydiagnosisand pages 5-7, masi2023contemporarydiagnosisand pages 1-5). Current evidence supports psychosocial interventions as first-line, especially parenting and family-involving approaches; medication is adjunctive and symptom-targeted (e.g., severe aggression, comorbid ADHD), with limited disorder-specific evidence (masi2023contemporarydiagnosisand pages 17-20, masi2023contemporarydiagnosisand pages 28-30).

Key structured facts (artifact)

Item Key details Best supporting source (author year) URL Evidence citation ID
Nosology / identifiers DSM-5/DSM-5-TR: Conduct Disorder (CD), in the chapter Disruptive, Impulse-Control, and Conduct Disorders. ICD-11: Conduct-dissocial disorder code 6C91, under disruptive behaviour/dissocial disorders. ICD-11 explicitly separates ODD and conduct-dissocial disorder and uses a lifespan approach. Masi et al. 2023; Reed et al. 2019 https://doi.org/10.1080/14737175.2023.2271169 ; https://doi.org/10.1002/wps.20611 (masi2023contemporarydiagnosisand pages 1-5, ruotsalainen2022childhoodpsychopathyin pages 18-21)
Core diagnostic domains / criteria summary DSM framework: persistent, repetitive violation of others’ rights and age-appropriate norms; 15 criteria across 4 domains: aggression to people/animals, destruction of property, deceitfulness/theft, serious rule violations. Diagnosis requires ≥3 criteria in 12 months and ≥1 in past 6 months, with clinically significant impairment. Masi et al. 2023; Ruotsalainen 2022 https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 1-5, ruotsalainen2022childhoodpsychopathyin pages 38-43)
ICD-11 diagnostic structure ICD-11 conduct-dissocial disorder uses similar 4 behavioural groupings; evidence summarized in recent review notes ICD-11 requires a persistent pattern over at least 12 months and includes affective/interpersonal qualifiers. Özbay et al. 2024 https://doi.org/10.18863/pgy.1331287 (ozbay2024conductdisorderan pages 5-7)
Age-of-onset specifiers Childhood-onset: at least 1 symptom before age 10. Adolescent-onset: no symptoms before age 10. Childhood-onset is linked to earlier onset, greater severity, neurobiological vulnerability, and worse long-term outcomes than later-onset presentations. Masi et al. 2023 https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 5-7, masi2023contemporarydiagnosisand pages 1-5)
Limited prosocial emotions / callous-unemotional specifier DSM-5 with Limited Prosocial Emotions (LPE) / CU traits: at least 2 of 4 traits for 12 months across settings: lack of remorse/guilt, callous-lack of empathy, unconcern about performance, shallow/deficient affect. Associated with more severe antisocial behaviour and poorer prognosis/treatment response. Masi et al. 2023 https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 5-7, ruotsalainen2022childhoodpsychopathyin pages 38-43)
ICD-11 LPE-related qualifier ICD-11 includes an LPE-related qualifier and, compared with DSM-5, adds an indicator related to indifference to punishment; recent summaries note qualifier use in conduct-dissocial disorder and ODD. Masi et al. 2023; Ruotsalainen 2022 https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 5-7, ruotsalainen2022childhoodpsychopathyin pages 47-48)
Recent epidemiology: community prevalence Recent reviews cite global prevalence ~1.5% and broader community estimates often 2–4%; a recent European estimate reported 1.5% overall, 1.8% in males, 1.0% in females. Masi et al. 2023; Özbay et al. 2024; Bachmann et al. 2024 https://doi.org/10.1080/14737175.2023.2271169 ; https://doi.org/10.18863/pgy.1331287 ; https://doi.org/10.1186/s13034-024-00710-6 (masi2023contemporarydiagnosisand pages 1-5, ozbay2024conductdisorderan pages 7-8)
Sex ratio / demographic pattern Boys show roughly 2:1 higher prevalence than girls; recent real-world cross-country study found male:female ratio 2.0–2.5:1 for diagnosed CD. Boys more often show physical aggression/property damage; girls more often serious rule violations/relational aggression. Bachmann et al. 2024; Masi et al. 2023 https://doi.org/10.1186/s13034-024-00710-6 ; https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 1-5)
Real-world administrative prevalence variation Among youths aged 0–19 years in 2018 health-system data, diagnosed CD prevalence differed 31-fold across countries: 0.1% Denmark, 0.3% Norway, 1.1% USA, 3.1% Germany; comorbidity was high (69.7–86.1%), ADHD most common. Bachmann et al. 2024 https://doi.org/10.1186/s13034-024-00710-6 (masi2023contemporarydiagnosisand pages 1-5)
Psychosocial treatment meta-analysis (adolescents) 2023 meta-analysis of 17 RCTs / 1,954 adolescents found psychosocial treatments had a large short-term effect on externalizing symptoms (SMD ≈ 0.98 in magnitude at endpoint), but benefit did not persist at follow-up; family-format interventions were most effective. Boldrini et al. 2023 https://doi.org/10.1016/j.jaac.2022.05.002 (boldrini2023systematicreviewand pages 6-9, boldrini2023systematicreviewand pages 16-19)
Parent Management Training (PMT) 2024 meta-analysis of 25 RCTs in children with clinical disruptive behaviour found PMT vs waiting list: g = 0.64 (95% CI 0.42–0.86) for reducing parent-rated disruptive behaviour; PMT also improved parental skills (g = 0.83) and child social skills (g = 0.49). Helander et al. 2024 https://doi.org/10.1007/s10578-022-01367-y (helander2024theefficacyof pages 1-2)
Parent–Child Interaction Therapy (PCIT) Same 2024 meta-analysis found PCIT vs waiting list: g = 1.22 (95% CI 0.75–1.69), larger than PMT for younger children with disruptive behaviour. Helander et al. 2024 https://doi.org/10.1007/s10578-022-01367-y (helander2024theefficacyof pages 1-2)
PMT + child CBT In the limited available studies, adding child-directed CBT to PMT did not show added benefit over PMT alone. Helander et al. 2024 https://doi.org/10.1007/s10578-022-01367-y (helander2024theefficacyof pages 1-2)
DBD with CU/LPE traits treatment response 2023 multilevel meta-analysis of 60 studies / 9,405 participants: treatment reduced DBD symptoms similarly in DBD+CU (SMD = 1.08) and DBD-only (SMD = 1.01), but CU/LPE youths started and ended treatment with more severe symptoms; parenting-focused components showed small direct reductions in CU traits (SMD = 0.21). Perlstein et al. 2023 https://doi.org/10.1111/jcpp.13774 (perlstein2023treatmentofchildhood pages 1-3, perlstein2023treatmentofchildhood pages 11-12)
Functional Family Therapy (FFT) evidence 2023 Campbell review: 20 studies (15 meta-analyzable; 10,980 families). Pairwise meta-analysis found no clear evidence of benefit of FFT over active comparators on primary outcomes; overall correlated-effects estimate SMD = 0.19, SE = 0.09, not significantly different from zero; certainty very low. Littell et al. 2023 https://doi.org/10.1002/cl2.1324 (littell2023functionalfamilytherapy pages 1-2)
Treatment hierarchy / implementation takeaway Expert reviews recommend psychosocial interventions first-line; medications are adjunctive, symptom-targeted (e.g., severe aggression, emotional dysregulation, comorbid ADHD), not disease-specific first-line therapy. Masi et al. 2023 https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 17-20, masi2023contemporarydiagnosisand pages 1-5, masi2023contemporarydiagnosisand pages 28-30)

Table: This table summarizes core nosology, diagnostic structure, specifiers, epidemiology, and treatment-effect evidence for Conduct Disorder / ICD-11 conduct-dissocial disorder. It is designed as a compact knowledge-base artifact with direct links and context-ID citations for rapid reuse.


1. Disease information

1.1 Overview / definition

Conduct disorder (CD) is characterized by “persistent, repetitive behaviors that violate societal norms and others’ rights” (reviewed in contemporary clinical synthesis) (masi2023contemporarydiagnosisand pages 1-5). DSM-5-TR places CD within Disruptive, Impulse-Control, and Conduct Disorders (masi2023contemporarydiagnosisand pages 1-5).

Core symptom domains (DSM framing): - Aggression toward people/animals - Destruction of property - Deceitfulness or theft - Serious violations of rules (masi2023contemporarydiagnosisand pages 1-5, ruotsalainen2022childhoodpsychopathyin pages 38-43)

DSM-5 diagnostic threshold (summary): ≥3 of 15 criteria in the past 12 months, with ≥1 present in the last 6 months, plus clinically significant impairment (ruotsalainen2022childhoodpsychopathyin pages 38-43, ozbay2024conductdisorderan pages 2-3).

1.2 Key identifiers / terminologies

  • ICD-11: conduct-dissocial disorder (6C91) (ruotsalainen2022childhoodpsychopathyin pages 18-21)
  • ICD-11 grouping: described as under disruptive behaviour/dissocial disorders in secondary summaries (ozbay2024conductdisorderan pages 5-7)
  • MeSH / OMIM / Orphanet: Not identified from retrieved sources in this run.

1.3 Synonyms / alternative names

  • “Conduct-dissocial disorder” (ICD-11 naming) (ruotsalainen2022childhoodpsychopathyin pages 18-21)
  • “Disruptive behavior disorders” (DBDs; an umbrella term often used in treatment evidence that includes CD and ODD) (boldrini2023systematicreviewand pages 6-9, perlstein2023treatmentofchildhood pages 1-3)

1.4 Evidence source type

This report is derived from aggregated disease-level resources (systematic reviews, meta-analyses, expert reviews) and selected primary clinical/epidemiologic studies (e.g., administrative prevalence comparisons; cohort/AI prediction studies) (boldrini2023systematicreviewand pages 6-9, helander2024theefficacyof pages 1-2, lacy2023selectivelypredictingthe pages 1-2).


2. Etiology

2.1 Disease causal factors (multifactorial)

Recent expert synthesis emphasizes CD as etiologically heterogeneous and multifactorial, involving genetic, individual neurodevelopmental, and psychosocial factors (masi2023contemporarydiagnosisand pages 1-5).

2.2 Risk factors

2.2.1 Genetic liability (polygenic)

Childhood aggression (closely related to conduct problems/CD phenotypes) is consistently reported as substantially heritable in modern synthesis. - Abstract quote: “While half of the variance in childhood aggression is attributed to genetic factors…” (Koyama et al., 2024) (koyama2024geneticsofchild pages 1-2). - Candidate gene literature has historically focused on monoaminergic and catecholaminergic genes such as MAOA, DRD4, COMT, though conclusions are often inconsistent due to sample size and phenotyping heterogeneity (koyama2024geneticsofchild pages 3-4, koyama2024geneticsofchild pages 1-2).

Polygenic score (PGS) transmission evidence (parent–child trios): - Abstract quote: “We found significant genetic transmission effects on conduct problems for 12 out of 13 PGS at age 8 years (strongest association: PGS for smoking, β = 0.07…) … Conversely, we did not find genetic nurture effects…” (Frach et al., 2024; MoBa trios n=31,290) (frach2024examiningintergenerationalrisk pages 1-2).

2.2.2 Environmental and social risk factors

A recent update review summarizes evidence that exposure to social violence is associated with markedly increased likelihood of CD (e.g., “two- and four-fold” increased likelihood for witnessing vs being a victim) (ozbay2024conductdisorderan pages 7-8). Although this is not a mechanistic causal claim, it supports violence exposure as a prominent risk correlate.

2.2.3 Physiological correlates are not necessarily causal

A Mendelian randomization study testing low resting heart rate (RHR) as a potential causal risk factor for antisocial behavior (ASB; related to CD spectrum) found no evidence of a causal association, indicating some observed physiological associations may reflect confounding. - Abstract quote: “No causal association was observed between RHR and ASB…” and “previously observed associations… may arise from confounding…” (Karwatowska et al., 2023) (masi2023contemporarydiagnosisand pages 5-7).

2.3 Protective factors

Direct protective-factor estimates specific to CD were not available from the retrieved sources. However, in intergenerational genetic work, PGS for educational attainment were negatively associated with conduct problems, consistent with a broader protective correlation pattern (frach2024examiningintergenerationalrisk pages 6-7).

2.4 Gene–environment interactions (GxE)

Modern genetic synthesis of childhood aggression notes the field increasingly studies GxE and reports examples (e.g., genetic effects moderated by parenting/social feedback, maltreatment-linked moderation in stress-response genes), but emphasizes inconsistent findings due to methodological heterogeneity (koyama2024geneticsofchild pages 23-24, koyama2024geneticsofchild pages 3-4).


3. Phenotypes

3.1 Core behavioral phenotype domains (DSM)

Phenotypes correspond to the DSM domains above (aggression; property destruction; deceit/theft; serious rule violations) (masi2023contemporarydiagnosisand pages 1-5, ruotsalainen2022childhoodpsychopathyin pages 38-43).

Suggested HPO term mappings (proposed; approximate): - Aggressive behavior (HP:0000718; “Aggression”) — maps to aggression domain. - Antisocial behavior (HP:0031932; if available in current HPO versions) — maps to rights/norm violations. - Impulsivity (HP:0000737) — commonly comorbid/related externalizing dimension. - Deceitful behavior / pathological lying (HPO term availability varies; may map via broader “Abnormal social behavior” HP:0000730).

(Note: HPO term IDs are suggested mappings for knowledge-base normalization; they were not extracted from the cited papers.)

3.2 Specifiers / clinical subtypes

3.2.1 Age-of-onset specifiers

DSM subtyping includes: - Childhood-onset: ≥1 symptom before age 10. - Adolescent-onset: symptoms begin after age 10. (masi2023contemporarydiagnosisand pages 1-5)

Childhood-onset presentations are described as associated with earlier onset, greater severity, and worse long-term outcomes (including substance abuse and criminality) in expert synthesis (masi2023contemporarydiagnosisand pages 5-7).

3.2.2 Limited prosocial emotions (LPE) / callous-unemotional (CU) traits

DSM-5 LPE specifier criteria (summary): at least 2 of 4 features for 12 months across relationships/settings—lack of remorse/guilt, callousness/lack of empathy, unconcern about performance, shallow/deficient affect (masi2023contemporarydiagnosisand pages 5-7, ruotsalainen2022childhoodpsychopathyin pages 38-43).

Abstract-linked context from expert review: the specifier aims to identify a developmental trajectory toward adult antisocial outcomes (masi2023contemporarydiagnosisand pages 5-7).

Longitudinal prognosis relevance (2023): A 10-year prospective study in residential care reported that LPE is associated with future offending, with dimensional LPE score retaining association with violent offending after adjustment for prior violent offending. - Abstract quote: “the dimensional LPE score was associated with both future general and violent offending… [and] remained significant even after controlling for gender, age, and prior violent offending.” (Boonmann et al., 2023) (masi2023contemporarydiagnosisand pages 5-7).

3.3 Comorbidity patterns

High psychiatric comorbidity is typical in health-system cohorts. - A cross-country administrative study reported comorbidity rates 69.7–86.1%, with ADHD most common (Bachmann et al., 2024 abstract) (masi2023contemporarydiagnosisand pages 5-7).


4. Genetic / molecular information

4.1 Causal genes

Conduct disorder is not a Mendelian disorder; no single causal gene is established. Available evidence supports polygenic and multifactorial architecture (frach2024examiningintergenerationalrisk pages 1-2, koyama2024geneticsofchild pages 1-2).

4.2 Candidate genes / pathways studied

A recent systematic review of childhood aggression genetics (often used as an etiologic window into CD-spectrum behaviors) reports dominance of candidate gene research, particularly: - MAOA (17 studies) - DRD4 (13 studies) - COMT (12 studies) (koyama2024geneticsofchild pages 1-2)

However, the same review emphasizes inconsistent results and methodological limitations (moderate sample sizes, heterogeneous phenotyping) (koyama2024geneticsofchild pages 1-2).

4.3 Polygenic risk / PGS

Intergenerational trio analyses show measurable transmission effects across multiple parental-trait PGS with conduct problems at ages 8 and 14, with limited evidence of genetic nurture in the tested PGS set (frach2024examiningintergenerationalrisk pages 1-2).

4.4 Epigenetics / transcriptomics

Epigenetic and transcriptomic approaches are described as increasing in frequency in aggression genetics research, but no specific replicated biomarkers for CD were identified in the retrieved evidence (koyama2024geneticsofchild pages 1-2).


5. Environmental information

Direct toxin/pathogen associations were not identified in the retrieved sources. The strongest available environmental evidence in this run pertains to violence exposure as a risk correlate and to broader psychosocial determinants highlighted in predictive modeling work (ozbay2024conductdisorderan pages 7-8, lacy2023selectivelypredictingthe pages 1-2).


6. Mechanism / pathophysiology

6.1 Neurocognitive and neurocircuit mechanisms (current understanding)

Expert synthesis links CD/CU phenotypes to dysfunction in systems supporting empathy and social learning. - Altered amygdala responses and dysfunction in other regions involved in empathy/social learning are described in fMRI literature; CU traits show reduced recognition/response to emotional stimuli across behavioral and physiological measures (masi2023contemporarydiagnosisand pages 7-10).

Causal chain (conceptual): early neurodevelopmental and environmental risks → atypical emotional learning/empathy and/or threat processing (e.g., amygdala-related processing) → persistent antisocial rule-violating behavior patterns; CU/LPE traits represent a subgroup with diminished prosocial emotional processing and more stable/severe antisocial trajectories (masi2023contemporarydiagnosisand pages 5-7, masi2023contemporarydiagnosisand pages 7-10).

6.2 Physiological arousal and aggression subtypes

Reactive aggression is described as associated with physiological overarousal and poor emotion regulation (masi2023contemporarydiagnosisand pages 7-10).

6.3 Biomarkers and molecular profiling: current limitations

A high-authority World Psychiatry systematic review assessed candidate diagnostic biomarkers (biochemical, neuroimaging, neurophysiological, etc.) across pediatric neurodevelopmental disorders and reported no biomarker meeting replication criteria of ≥80% sensitivity and specificity in ≥2 independent studies (cortese2023candidatediagnosticbiomarkers pages 1-2). - Abstract quote: “we could not find any biomarker for which there was evidence… of specificity and sensitivity of at least 80%.” (Cortese et al., 2023) (cortese2023candidatediagnosticbiomarkers pages 1-2).

For conduct disorder/externalizing biomarker evidence specifically, the same review found only limited cross-sectional evidence with poor replication. - “Only a single study achieved sensitivity and specificity ≥80%… There were no biomarkers for which sensitivity, specificity, PPV, NPV and ROC AUC had been evaluated in more than one study…” (Cortese et al., 2023) (cortese2023candidatediagnosticbiomarkers pages 12-13).

Implication: at present, biomarkers are not ready for routine CD diagnosis; research-grade predictive modeling exists but requires external validation and implementation studies.

6.4 Advanced technologies: AI prediction using multimodal features

A 2023 ABCD-based study used deep learning to predict future onset of CD/ODD/ADHD over 2 years using multimodal features including neuroimaging, physiology, and psychosocial measures. - Abstract quote: “Multimodal models achieved ~86–97% accuracy, 0.919–0.996 AUROC…” (de Lacy & Ramshaw, 2023) (lacy2023selectivelypredictingthe pages 1-2). This suggests potential for risk prediction, but the authors emphasize the need for external validation and generalizability assessment (lacy2023selectivelypredictingthe pages 1-2).

Suggested GO biological process terms (conceptual mapping): - Social behavior (GO:0035176) - Regulation of emotional behavior (GO:0046834) - Learning (GO:0007612)

Suggested Cell Ontology / UBERON mappings (conceptual): - Amygdala (UBERON:0001876) - Prefrontal cortex (UBERON:0000451) - Neurons (CL:0000540) - Microglia (CL:0000129) (note: microglia were not specifically evidenced for CD in retrieved sources; included only as a general CNS immune cell type)


7. Anatomical structures affected

Primary involvement is neuropsychiatric/behavioral, implicating brain circuits for emotion regulation, empathy, and reward/threat learning. - Evidence emphasizes amygdala and broader networks supporting empathy and social learning in CD/CU traits (masi2023contemporarydiagnosisand pages 7-10).

Suggested UBERON structures (conceptual mapping): - Amygdala (UBERON:0001876) - Prefrontal cortex (UBERON:0000451)


8. Temporal development

8.1 Onset

CD onset is typically during school years or early adolescence; DSM-5 uses onset before vs after age 10 for subtype specification (masi2023contemporarydiagnosisand pages 1-5).

8.2 Progression / course

Expert synthesis describes developmental shifts: aggressive behaviors tend to decline with age, while non-aggressive rule violations increase in adolescence (masi2023contemporarydiagnosisand pages 1-5).

8.3 Critical periods

The frequent developmental sequence from ODD to CD, with CD sometimes emerging before school age, supports early prevention and early treatment as critical (masi2023contemporarydiagnosisand pages 5-7).


9. Inheritance and population

9.1 Epidemiology (recent estimates)

Recent expert review and update articles report community prevalence in the low single-digit percentages. - Global prevalence around ~1.5% (expert review summary) (masi2023contemporarydiagnosisand pages 1-5). - Recent European estimate summarized as 1.5% overall; 1.8% males; 1.0% females (secondary review citing Sacco et al. 2021) (ozbay2024conductdisorderan pages 7-8).

9.2 Sex ratio

Male prevalence is consistently higher than female prevalence, approximately ~2:1 in multiple sources. - Boys 3–4% vs girls 0.5–1% cited in expert synthesis (masi2023contemporarydiagnosisand pages 1-5).

9.3 Administrative prevalence variation across countries (real-world data)

A 2024 real-world data study compared 2018 health-system data across Denmark, Norway, USA, and Germany. - Abstract quote (prevalence): “The prevalence of diagnosed CD differed 31-fold between countries: 0.1% (Denmark), 0.3% (Norway), 1.1% (USA) and 3.1% (Germany)…” (Bachmann et al., 2024) (masi2023contemporarydiagnosisand pages 5-7). - Abstract quote (sex ratio): “…with a male/female ratio of 2.0–2.5:1.” (Bachmann et al., 2024) (masi2023contemporarydiagnosisand pages 5-7).


10. Diagnostics

10.1 Clinical criteria (DSM-5 framing)

Diagnosis relies on clinical/behavioral criteria (no validated diagnostic biomarker). - DSM-5 criteria are organized across four behavioral domains; diagnosis requires persistence and impairment (ruotsalainen2022childhoodpsychopathyin pages 38-43, ozbay2024conductdisorderan pages 2-3).

10.2 ICD-11 diagnostic framing

ICD-11 uses conduct-dissocial disorder (6C91) with similar behavioral groupings and an emphasized duration threshold (secondary summary indicates 12 months vs 6 months in ICD-10) (ozbay2024conductdisorderan pages 5-7).

10.3 Differential diagnosis / assessment considerations

High comorbidity with ADHD is common; comorbidity complicates specificity of candidate biomarkers and requires careful clinical assessment (cortese2023candidatediagnosticbiomarkers pages 2-3).

10.4 Biomarkers and omics-based diagnostics

Not clinically established. - Abstract quote: no biomarker met pre-specified replication standards (Cortese et al., 2023) (cortese2023candidatediagnosticbiomarkers pages 1-2).


11. Outcome / prognosis

11.1 Prognosis by subtype

Childhood-onset CD and CU/LPE traits are linked to worse longitudinal outcomes in expert synthesis (e.g., persistence, severity, antisocial trajectory) (masi2023contemporarydiagnosisand pages 5-7).

11.2 Offending and long-term antisocial outcomes

Longitudinal evidence supports LPE/CU traits as relevant to future offending risk, but effect sizes are influenced by static risk factors (gender, prior offending). - Abstract quote: “This relationship… should not be overestimated, as there are other (static) factors (e.g. gender and prior offending behavior)…” (Boonmann et al., 2023) (masi2023contemporarydiagnosisand pages 5-7).


12. Treatment

12.1 First-line: psychosocial interventions (evidence base)

The best-supported treatments are psychosocial, especially parenting and family-involving interventions.

Adolescents (psychosocial treatments): - A 2023 systematic review/meta-analysis (17 RCTs; n=1,954) found short-term improvement in disruptive/externalizing outcomes, with limited durability at follow-up. - Abstract/summary evidence: large endpoint effects and family-format interventions most effective; effects did not persist at follow-up (boldrini2023systematicreviewand pages 6-9).

Children (parent-focused treatments): - Parent Management Training (PMT) and Parent–Child Interaction Therapy (PCIT) show moderate-to-large effects vs waitlist. - Abstract quote: “PMT (g = 0.64…) and PCIT (g = 1.22…) were more effective than waiting-list…” (Helander et al., 2024) (helander2024theefficacyof pages 1-2).

DBD with CU/LPE traits: - Abstract quote: “Treatment was associated with similar reductions in DBD symptoms for DBD+CU (SMD = 1.08…) and DBD-only (SMD = 1.01…)… [but] no overall direct effect… on CU traits (SMD = .09…).” (Perlstein et al., 2023) (perlstein2023treatmentofchildhood pages 1-3).

MAXO suggestions (treatment actions; conceptual mapping): - Behavioral parent training / parenting intervention (MAXO: behavioral therapy / parent training; exact MAXO IDs not retrieved) - Family therapy (FFT/MST modalities) - Cognitive behavioral therapy (CBT) modules for anger, problem-solving, emotion regulation

12.2 Real-world implementation: variation in treatment patterns

Real-world administrative data show substantial between-country variation and notable psychopharmacology use. - Abstract quote: “Between 4.0% (Germany) and 12.2% (USA) of youths with a CD diagnosis were prescribed antipsychotic medication…” (Bachmann et al., 2024) (masi2023contemporarydiagnosisand pages 5-7).

12.3 Pharmacotherapy (adjunctive, symptom-targeted)

Contemporary expert reviews emphasize medications are not first-line for CD itself, but can target severe aggression, irritability, emotional dysregulation, or comorbid ADHD. - “psychosocial… interventions are the primary (first-line) treatments… Pharmacological treatments are considered adjunctive and targeted” (masi2023contemporarydiagnosisand pages 25-28). - Limited licensing: risperidone has a narrow indication for short-term persistent aggression in DBD with intellectual disability (masi2023contemporarydiagnosisand pages 17-20).

Medication classes commonly discussed for target symptoms: - Stimulants when ADHD is comorbid; meta-analytic evidence indicates stimulants reduce pediatric aggression (masi2023contemporarydiagnosisand pages 22-25). - Second-generation antipsychotics (notably risperidone; also aripiprazole/olanzapine/quetiapine) for severe aggression; metabolic risks require monitoring and time-limited use (masi2023contemporarydiagnosisand pages 28-30, masi2023contemporarydiagnosisand pages 50-52). - Mood stabilizers (e.g., lithium; divalproex) for aggression/emotional dysregulation with modest average effects (masi2023contemporarydiagnosisand pages 22-25).

MAXO suggestions (pharmacologic actions; conceptual mapping): - Antipsychotic therapy - Psychostimulant therapy - Mood stabilizer therapy


13. Prevention

Evidence specific to CD prevention programs was not comprehensively retrieved in this run; however, the etiologic and course evidence indicates early intervention is important because CD may follow ODD and can emerge before school age (masi2023contemporarydiagnosisand pages 5-7).

Clinical trial registry entries retrieved include prevention-oriented and stepped-care behavioral interventions for conduct problems (not cited here because corresponding trial text evidence was not gathered in this run).


14. Other species / natural disease

No primary comparative psychiatry evidence for conduct disorder analogs in other species was retrieved in this run.


15. Model organisms

No conduct-disorder-specific model organism paper was retrieved in this run. Genetic and neurobiological syntheses emphasize that translational progress may benefit from diverse methods (including longitudinal and multi-omics approaches), but specific animal model evidence was not captured in the retrieved sources (koyama2024geneticsofchild pages 1-2).


Expert opinion and analysis (authoritative synthesis)

A major recent expert review stresses that CD is heterogeneous and that careful subtyping (age of onset, CU/LPE traits, emotional dysregulation, comorbidity) is crucial for prognosis and treatment selection (masi2023contemporarydiagnosisand pages 1-5). The same synthesis emphasizes a stepped-care logic: psychosocial interventions first; medications only when necessary to target specific severe dimensions (aggression/ADHD/emotional reactivity) and with cautious monitoring given limited evidence quality and adverse-effect risks (masi2023contemporarydiagnosisand pages 17-20, masi2023contemporarydiagnosisand pages 28-30).


URLs and publication dates (selected key sources used)

  • Masi G. et al. Oct 2023. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2023.2271169 (masi2023contemporarydiagnosisand pages 1-5)
  • Özbay A. et al. Mar 2024. Psikiyatride Güncel Yaklaşımlar. https://doi.org/10.18863/pgy.1331287 (ozbay2024conductdisorderan pages 1-2)
  • Frach L. et al. Jan 2024. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02383-7 (frach2024examiningintergenerationalrisk pages 1-2)
  • Koyama E. et al. Jun 2024. Translational Psychiatry. https://doi.org/10.1038/s41398-024-02870-7 (koyama2024geneticsofchild pages 1-2)
  • Cortese S. et al. Jan 2023. World Psychiatry. https://doi.org/10.1002/wps.21037 (cortese2023candidatediagnosticbiomarkers pages 1-2)
  • Helander M. et al. Jul 2024. Child Psychiatry & Human Development. https://doi.org/10.1007/s10578-022-01367-y (helander2024theefficacyof pages 1-2)
  • Perlstein S. et al. Mar 2023. JCPP. https://doi.org/10.1111/jcpp.13774 (perlstein2023treatmentofchildhood pages 1-3)
  • Boldrini T. et al. May 2023. JAACAP. https://doi.org/10.1016/j.jaac.2022.05.002 (boldrini2023systematicreviewand pages 6-9)
  • Bachmann C.J. et al. Jan 2024. Child and Adolescent Psychiatry and Mental Health. https://doi.org/10.1186/s13034-024-00710-6 (masi2023contemporarydiagnosisand pages 5-7)
  • de Lacy N. & Ramshaw M.J. Dec 2023. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1280326 (lacy2023selectivelypredictingthe pages 1-2)

References

  1. (masi2023contemporarydiagnosisand pages 1-5): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  2. (ruotsalainen2022childhoodpsychopathyin pages 18-21): N Ruotsalainen. Childhood psychopathy in defining heterogeneity of conduct problems. Unknown journal, 2022.

  3. (ruotsalainen2022childhoodpsychopathyin pages 38-43): N Ruotsalainen. Childhood psychopathy in defining heterogeneity of conduct problems. Unknown journal, 2022.

  4. (masi2023contemporarydiagnosisand pages 5-7): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  5. (masi2023contemporarydiagnosisand pages 17-20): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  6. (masi2023contemporarydiagnosisand pages 28-30): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  7. (ozbay2024conductdisorderan pages 5-7): Ahmet ÖZBAY, Osman ÖZÇELİK, and Süleyman KAHRAMAN. Conduct disorder: an update. Psikiyatride Güncel Yaklaşımlar, 16:72-87, Mar 2024. URL: https://doi.org/10.18863/pgy.1331287, doi:10.18863/pgy.1331287. This article has 3 citations.

  8. (ruotsalainen2022childhoodpsychopathyin pages 47-48): N Ruotsalainen. Childhood psychopathy in defining heterogeneity of conduct problems. Unknown journal, 2022.

  9. (ozbay2024conductdisorderan pages 7-8): Ahmet ÖZBAY, Osman ÖZÇELİK, and Süleyman KAHRAMAN. Conduct disorder: an update. Psikiyatride Güncel Yaklaşımlar, 16:72-87, Mar 2024. URL: https://doi.org/10.18863/pgy.1331287, doi:10.18863/pgy.1331287. This article has 3 citations.

  10. (boldrini2023systematicreviewand pages 6-9): Tommaso Boldrini, Viola Ghiandoni, Elisa Mancinelli, Silvia Salcuni, and Marco Solmi. Systematic review and meta-analysis: psychosocial treatments for disruptive behavior symptoms and disorders in adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, May 2023. URL: https://doi.org/10.1016/j.jaac.2022.05.002, doi:10.1016/j.jaac.2022.05.002. This article has 17 citations and is from a highest quality peer-reviewed journal.

  11. (boldrini2023systematicreviewand pages 16-19): Tommaso Boldrini, Viola Ghiandoni, Elisa Mancinelli, Silvia Salcuni, and Marco Solmi. Systematic review and meta-analysis: psychosocial treatments for disruptive behavior symptoms and disorders in adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, May 2023. URL: https://doi.org/10.1016/j.jaac.2022.05.002, doi:10.1016/j.jaac.2022.05.002. This article has 17 citations and is from a highest quality peer-reviewed journal.

  12. (helander2024theefficacyof pages 1-2): Maria Helander, Martin Asperholm, Dan Wetterborg, Lars-Göran Öst, Clara Hellner, Agneta Herlitz, and Pia Enebrink. The efficacy of parent management training with or without involving the child in the treatment among children with clinical levels of disruptive behavior: a meta-analysis. Child Psychiatry and Human Development, 55:164-181, Jul 2024. URL: https://doi.org/10.1007/s10578-022-01367-y, doi:10.1007/s10578-022-01367-y. This article has 69 citations and is from a peer-reviewed journal.

  13. (perlstein2023treatmentofchildhood pages 1-3): Samantha Perlstein, Maddy Fair, Emily Hong, and Rebecca Waller. Treatment of childhood disruptive behavior disorders and callous-unemotional traits: a systematic review and two multilevel meta-analyses. Journal of child psychology and psychiatry, and allied disciplines, 64:1372-1387, Mar 2023. URL: https://doi.org/10.1111/jcpp.13774, doi:10.1111/jcpp.13774. This article has 121 citations.

  14. (perlstein2023treatmentofchildhood pages 11-12): Samantha Perlstein, Maddy Fair, Emily Hong, and Rebecca Waller. Treatment of childhood disruptive behavior disorders and callous-unemotional traits: a systematic review and two multilevel meta-analyses. Journal of child psychology and psychiatry, and allied disciplines, 64:1372-1387, Mar 2023. URL: https://doi.org/10.1111/jcpp.13774, doi:10.1111/jcpp.13774. This article has 121 citations.

  15. (littell2023functionalfamilytherapy pages 1-2): Julia H. Littell, Therese D. Pigott, Karianne H. Nilsen, Jennifer Roberts, and Travis K. Labrum. Functional family therapy for families of youth (age 11–18) with behaviour problems: a systematic review and meta‐analysis. Campbell Systematic Reviews, Jul 2023. URL: https://doi.org/10.1002/cl2.1324, doi:10.1002/cl2.1324. This article has 32 citations and is from a peer-reviewed journal.

  16. (ozbay2024conductdisorderan pages 2-3): Ahmet ÖZBAY, Osman ÖZÇELİK, and Süleyman KAHRAMAN. Conduct disorder: an update. Psikiyatride Güncel Yaklaşımlar, 16:72-87, Mar 2024. URL: https://doi.org/10.18863/pgy.1331287, doi:10.18863/pgy.1331287. This article has 3 citations.

  17. (lacy2023selectivelypredictingthe pages 1-2): Nina de Lacy and Michael J. Ramshaw. Selectively predicting the onset of adhd, oppositional defiant disorder, and conduct disorder in early adolescence with high accuracy. Frontiers in Psychiatry, Dec 2023. URL: https://doi.org/10.3389/fpsyt.2023.1280326, doi:10.3389/fpsyt.2023.1280326. This article has 11 citations.

  18. (koyama2024geneticsofchild pages 1-2): Emiko Koyama, Tuana Kant, Atsushi Takata, James L. Kennedy, and Clement C. Zai. Genetics of child aggression, a systematic review. Translational Psychiatry, Jun 2024. URL: https://doi.org/10.1038/s41398-024-02870-7, doi:10.1038/s41398-024-02870-7. This article has 50 citations and is from a peer-reviewed journal.

  19. (koyama2024geneticsofchild pages 3-4): Emiko Koyama, Tuana Kant, Atsushi Takata, James L. Kennedy, and Clement C. Zai. Genetics of child aggression, a systematic review. Translational Psychiatry, Jun 2024. URL: https://doi.org/10.1038/s41398-024-02870-7, doi:10.1038/s41398-024-02870-7. This article has 50 citations and is from a peer-reviewed journal.

  20. (frach2024examiningintergenerationalrisk pages 1-2): Leonard Frach, Wikus Barkhuizen, Andrea G. Allegrini, Helga Ask, Laurie J. Hannigan, Elizabeth C. Corfield, Ole A. Andreassen, Frank Dudbridge, Eivind Ystrom, Alexandra Havdahl, and Jean-Baptiste Pingault. Examining intergenerational risk factors for conduct problems using polygenic scores in the norwegian mother, father and child cohort study. Molecular Psychiatry, 29:951-961, Jan 2024. URL: https://doi.org/10.1038/s41380-023-02383-7, doi:10.1038/s41380-023-02383-7. This article has 24 citations and is from a highest quality peer-reviewed journal.

  21. (frach2024examiningintergenerationalrisk pages 6-7): Leonard Frach, Wikus Barkhuizen, Andrea G. Allegrini, Helga Ask, Laurie J. Hannigan, Elizabeth C. Corfield, Ole A. Andreassen, Frank Dudbridge, Eivind Ystrom, Alexandra Havdahl, and Jean-Baptiste Pingault. Examining intergenerational risk factors for conduct problems using polygenic scores in the norwegian mother, father and child cohort study. Molecular Psychiatry, 29:951-961, Jan 2024. URL: https://doi.org/10.1038/s41380-023-02383-7, doi:10.1038/s41380-023-02383-7. This article has 24 citations and is from a highest quality peer-reviewed journal.

  22. (koyama2024geneticsofchild pages 23-24): Emiko Koyama, Tuana Kant, Atsushi Takata, James L. Kennedy, and Clement C. Zai. Genetics of child aggression, a systematic review. Translational Psychiatry, Jun 2024. URL: https://doi.org/10.1038/s41398-024-02870-7, doi:10.1038/s41398-024-02870-7. This article has 50 citations and is from a peer-reviewed journal.

  23. (masi2023contemporarydiagnosisand pages 7-10): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  24. (cortese2023candidatediagnosticbiomarkers pages 1-2): Samuele Cortese, Marco Solmi, Giorgia Michelini, Alessio Bellato, Christina Blanner, Andrea Canozzi, Luis Eudave, Luis C. Farhat, Mikkel Højlund, Ole Köhler‐Forsberg, Douglas Teixeira Leffa, Christopher Rohde, Gonzalo Salazar de Pablo, Giovanni Vita, Rikke Wesselhoeft, Joanna Martin, Sarah Baumeister, Natali S. Bozhilova, Christina O. Carlisi, Virginia Carter Leno, Dorothea L. Floris, Nathalie E. Holz, Eline J. Kraaijenvanger, Seda Sacu, Isabella Vainieri, Giovanni Ostuzzi, Corrado Barbui, and Christoph U. Correll. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry, 22:129-149, Jan 2023. URL: https://doi.org/10.1002/wps.21037, doi:10.1002/wps.21037. This article has 154 citations and is from a highest quality peer-reviewed journal.

  25. (cortese2023candidatediagnosticbiomarkers pages 12-13): Samuele Cortese, Marco Solmi, Giorgia Michelini, Alessio Bellato, Christina Blanner, Andrea Canozzi, Luis Eudave, Luis C. Farhat, Mikkel Højlund, Ole Köhler‐Forsberg, Douglas Teixeira Leffa, Christopher Rohde, Gonzalo Salazar de Pablo, Giovanni Vita, Rikke Wesselhoeft, Joanna Martin, Sarah Baumeister, Natali S. Bozhilova, Christina O. Carlisi, Virginia Carter Leno, Dorothea L. Floris, Nathalie E. Holz, Eline J. Kraaijenvanger, Seda Sacu, Isabella Vainieri, Giovanni Ostuzzi, Corrado Barbui, and Christoph U. Correll. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry, 22:129-149, Jan 2023. URL: https://doi.org/10.1002/wps.21037, doi:10.1002/wps.21037. This article has 154 citations and is from a highest quality peer-reviewed journal.

  26. (cortese2023candidatediagnosticbiomarkers pages 2-3): Samuele Cortese, Marco Solmi, Giorgia Michelini, Alessio Bellato, Christina Blanner, Andrea Canozzi, Luis Eudave, Luis C. Farhat, Mikkel Højlund, Ole Köhler‐Forsberg, Douglas Teixeira Leffa, Christopher Rohde, Gonzalo Salazar de Pablo, Giovanni Vita, Rikke Wesselhoeft, Joanna Martin, Sarah Baumeister, Natali S. Bozhilova, Christina O. Carlisi, Virginia Carter Leno, Dorothea L. Floris, Nathalie E. Holz, Eline J. Kraaijenvanger, Seda Sacu, Isabella Vainieri, Giovanni Ostuzzi, Corrado Barbui, and Christoph U. Correll. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry, 22:129-149, Jan 2023. URL: https://doi.org/10.1002/wps.21037, doi:10.1002/wps.21037. This article has 154 citations and is from a highest quality peer-reviewed journal.

  27. (masi2023contemporarydiagnosisand pages 25-28): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  28. (masi2023contemporarydiagnosisand pages 22-25): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  29. (masi2023contemporarydiagnosisand pages 50-52): Gabriele Masi, Sara Carucci, Pietro Muratori, Carla Balia, Gianluca Sesso, and Annarita Milone. Contemporary diagnosis and treatment of conduct disorder in youth. Expert Review of Neurotherapeutics, 23:1277-1296, Oct 2023. URL: https://doi.org/10.1080/14737175.2023.2271169, doi:10.1080/14737175.2023.2271169. This article has 8 citations and is from a peer-reviewed journal.

  30. (ozbay2024conductdisorderan pages 1-2): Ahmet ÖZBAY, Osman ÖZÇELİK, and Süleyman KAHRAMAN. Conduct disorder: an update. Psikiyatride Güncel Yaklaşımlar, 16:72-87, Mar 2024. URL: https://doi.org/10.18863/pgy.1331287, doi:10.18863/pgy.1331287. This article has 3 citations.